ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2016
Use of Healthcare Services Following Severe Hypoglycemia in Patients with Diabetes: Analysis of Real-World Data.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Cost-effectiveness of a Novel Hypoglycaemia Programme: The 'HARPdoc vs BGAT' RCT.Diabetic medicine : a journal of the British Diabetic Association · 2024Trial
- Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK.BMJ open diabetes research & care · 2019Trial
- Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis.Endocrinology, diabetes & metabolism · 2020Article
- Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Article
- Hypoglycemia incidence and awareness among insulin-treated patients with diabetes: the HAT study in Brazil.Diabetology & metabolic syndrome · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSevere hypoglycemia is a burden for both patients and the healthcare system payer alike. This study aimed to quantify the resource use associated with a severe hypoglycemic event (SHE) in patients with diabetes.
methodsThis retrospective cohort study compared resource use (e.g., physician visits, hospitalizations, and medications) 1 month pre- and post-SHE among patients with type 1 (T1D) or type 2 diabetes (T2D) from a large not-for-profit healthcare provider.
resultsFrom 2005 to 2014, 284 patients with T1D (52.5% male, mean age 29.8 years, mean HbA1c 7.9%) and 3691 patients with T2D (47.6% male, mean age 67.1 years, mean HbA1c 7.3%) were eligible for inclusion in the study. In total, 95.4% of patients with T1D and 32.8% of patients with T2D were insulin treated, while 3.5% of patients with T1D and 70.4% of patients with T2D were treated with oral drugs that could cause hypoglycemia (sulfonylureas or meglitinides). Hospital admissions increased by 95% in T1D and 127% in T2D (P < 0.001) 1 month post-SHE versus 1 month pre-SHE. Of those admitted to hospital (T1D n = 59; T2D n = 1214), the mean length of stay was significantly longer during the month post- versus pre-SHE [2.08 vs. 0.88 days, P = 0.036 (T1D) and 4.17 vs. 1.45 days, P < 0.001 (T2D)]. Outpatient visits also increased by 37% for T1D and 47% for T2D between these two time periods (P < 0.001). The total monthly expense per patient increased by 46% and 87% for T1D and T2D, respectively, from $485 pre-SHE to $708 post-SHE for T1D, and from $601 pre-SHE to $1121 post-SHE for T2D (P < 0.001). The greatest expense was hospital care, with increases of 179% and 166% for T1D and T2D, respectively, to $312 and $706 per patient/month.
conclusionThis real-world analysis from a large diabetes registry indicates an increased use of healthcare services, including more frequent and prolonged hospital admissions and outpatient visits after an SHE, which resulted in an increase in healthcare expense.
fundingNovo Nordisk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.